首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1812619

乳癌抗体药物复合体的全球市场:市场机会，专利，价格，认证核可药的销售额和临床试验趋势(2030年)

Global Breast Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030

出版日期: 2025年09月01日 | 出版商:

KuicK Research | 英文 330 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球乳癌抗体-药物偶联物市场：市场机会、专利、定价、核准药物销售及临床试验趋势（2030 年）报告结果及重点

研究方法
全球乳癌抗体-药物偶联物市场机会：到 2030 年将超过 200 亿美元
全球及各地区市场规模洞察（年度及季度）：2020 年 - 2025 年上半年
核准乳癌抗体-药物偶联物销售趋势：2020-2025 年
全球癌症抗体-药物偶联物市场预测：2026-2030 年
专利、剂量和价格分析已获准乳癌抗体-药物偶联物
临床试验中的乳癌抗体-药物偶联物：超过100种药物
按公司、国家、适应症和阶段划分的乳癌抗体-药物偶联物临床试验洞察
癌症抗体-药物偶联物开发平台和公司

乳癌治疗对抗体-药物偶联物的需求及本报告的意义

抗体药物偶联物 (ADC) 正迅速成为对抗乳癌的重要创新，尤其是在满足 HER2 阳性和 HER2 低表达肿瘤患者未满足的需求方面。这些药物利用单株抗体的精准标靶性和化疗药物的强效细胞毒性，在避免全身毒性的同时达到局部肿瘤破坏。全球市场已认识到这一潜力，预计乳癌 ADC 的销售额将在 2024 年超过 70 亿美元，到 2030 年将成长两倍。

本报告旨在为乳癌 ADC 的开发提供及时且具有战略意义的见解。随着该领域从早期研究发展到广泛的临床应用，从药物开发商到投资者等利益相关者都需要了解临床开发、试验设计、平台技术和商业化路径的最新资讯。本报告按地区、亚型和临床试验阶段提取精炼的全球数据，为决策者提供指导和塑造乳癌治疗方向所需的见解。

报告中包含的临床试验见解

本报告对乳癌 ADC 候选化合物进行了广泛的分析，包括已核准的乳癌 ADC 从 I 期早期到 III 期晚期试验的数据。这些试验涵盖美国、欧洲、中国和澳洲等主要地区。临床数据不仅涵盖传统的 HER2 阳性患者，还涵盖 HER2 低表达患者群体，这是乳癌精准医疗的新兴领域。本报告包含对 120 多种乳癌抗体-药物偶联物的洞察。

正在考虑的最重要变数包括治疗策略（单药治疗或合併治疗）、临床试验申办者（学术机构、公司）以及 HER2 以外的分子标靶（TROP2、B7-H4 等）。后期研发管线中的关键候选药物包括 Enhertu、Trodelvy 和 Dataloway，以及 DP303c、isalontamab brengitecan 和 JSKN003 等新进者。 sacituzumab govitecan 与 pembrolizumab 或曲妥珠单抗的组合也正在研究中，以解决抗药性机制。伴随诊断（包括罗氏基于人工智慧的 TROP2 检测）也包含在研究设计中，以便基于生物标记进行患者选择。这些洞察共同描绘出全球最具成效和最成功的临床活动。

从事乳癌抗体偶联药物研发的顶尖公司

许多製药公司和尖端生物技术公司正在定义乳癌抗体偶联药物市场。第一三共和阿斯特捷利康在全球销售额方面领先同类领导者Enhertu。罗氏和基因泰克继续积极推进Kadcyla和诊断产品。最近被辉瑞收购的Seagen正在增强其产品线深度，而ADC Therapeutics和Mersana Therapeutics则凭藉差异化平台获得关注。

荣昌生物和Zydus Cadila等新兴公司正在扩大其地理覆盖范围，尤其是在亚洲。每家公司都在开发新的有效载荷、连接体和抗体形式，以降低毒性并提高临床疗效。这些发展不仅代表技术创新，也代表着推动全球开发和可近性的激烈竞争。

技术平台、合作与协议

技术平台是乳癌 ADC 领域最大的差异化因素。各公司正在优化偶联方法、连接体化学和有效载荷递送系统。例如，双特异性 ADC (BsADC) 可以同时靶向两种抗原，是应对肿瘤异质性的新一代解决方案。 Enhertu 的成功部分归功于其高药物抗体比和稳定的连接体技术。

合作研究也正在推动公司扩张。辉瑞收购 Siegen 后，获得了一个专有的 ADC 平台。学术研究机构与产业界之间的合作，例如临床试验伙伴关係，正在加速候选化合物的开发。许可协议和透过 CDMO 提供的本地生产支援也在扩大市场准入，尤其是在印度、中国和拉丁美洲等新兴市场。

报告揭示乳癌抗体-药物偶联物的未来发展方向

本报告预测，乳癌仍将是ADC创新和商业化的主要适应症。随着越来越多的候选药物进入后期临床试验，以及联合方案显示出早期疗效，未来将朝着更个人化、标靶治疗的方向发展。值得关注的新兴创新包括双特异性ADC、生物标记检测的增加、新辅助/辅助治疗以及在早期疾病中的应用。

监管势头、投资资本和科学进步都在汇聚，为ADC成为乳癌治疗的基石铺平道路。凭藉活跃的研发管线、国际审批和更广泛的适应症，乳癌ADC有望改变癌症治疗的面貌。

Research Methodology
Global Breast Cancer Antibody Drug Conjugates Market Opportunity: > US$ 20 Billion By 2030
Global & Regional Market Size Insight (Yearly & Quarterly): 2020 Till H1'2025
Approved Breast Cancer Antibody Drug Conjugates Sales Insight : 2020 Till 2025
Global Cancer Antibody Drug Conjugates Market Forecast: 2026 Till 2030
Approved Breast Cancer Antibody Drug Conjugates Patent, Dosage and Price Analysis
Breast Cancer Antibody Drug Conjugates In Clinical Trials: > 100 Drugs
Breast Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase
Cancer Antibody Drug Conjugates Development Platforms By Company

Need For Antibody Drug Conjugates In Breast Cancer Treatment & Why This Report

Antibody drug conjugates (ADCs) are rapidly becoming an essential innovation in the battle against breast cancer, specifically in fulfilling the unmet needs of patients with HER2-positive and HER2-low tumors. These drugs leverage the precision targeting of monoclonal antibodies along with the potent cytotoxic effects of chemotherapeutic drugs to achieve more localized destruction of the tumor while avoiding systemic toxicity. The global market has identified this potential, with breast cancer ADCs sales exceeding US$ 7 Billion in 2024, and further expected to triple by 2030.

The purpose of this report is to provide an incisive, timely, and strategic insight into the developing landscape of breast cancer ADCs. As the space evolves from nascent research into broad clinical acceptance, stakeholders, ranging from pharmaceutical developers to investors, need current intelligence on clinical developments, trial design, platform technologies, and commercialization avenues. By boiling down sophisticated global data by geography, subtype, and trial phase, this report arms decision-makers with the insights needed to navigate and shape the direction of breast cancer treatment.

Clinical Trials Insight Included In Report

The report contains extensive analysis of ADC candidates for breast cancer, from early Phase 1 to late stage Phase 3 trials, including extensive data on already approved breast cancer ADCs These trials span across key geographies like the US, Europe, China, and Australia. Clinical data not only target the classic HER2-positive patients but also the emerging HER2-low patient population, a new area in breast cancer precision medicine. Report includes insight on more than 120 breast cancer antiboduies drug conjugates.

The most crucial variables examined are therapeutic strategy (monotherapy versus combination regimens), sponsorship of trials (academic centers versus industry), and molecular targets other than HER2, i.e., TROP2 and B7-H4. The key contenders in the late-stage pipeline are Enhertu, Trodelvy, Datroway, and new entrants such as DP303c, Izalontamab brengitecan, and JSKN003. Combination studies, such as sacituzumab govitecan with pembrolizumab or trastuzumab, are also investigated, providing solutions to mechanisms of resistance. Companion diagnostics, including Roche's TROP2 assay based on AI, are also included in trial designs to enable biomarker-based patient selection. Combined, all these insights chart the most productive and successful clinical activities globally.

Top Companies Working On R&D of Breast Cancer Antibody Drug Conjugates

A number of pharma titans and cutting-edge biotech players are defining the breast cancer ADC market. Daiichi Sankyo and AstraZeneca dominate with Enhertu, the category leader in global sales. Roche and Genentech remain active through Kadcyla and diagnostics. Seagen, having just been acquired by Pfizer, is adding pipeline depth, while ADC Therapeutics and Mersana Therapeutics are gaining traction with differentiated platforms.

Emerging companies such as RemeGen and Zydus Cadila are broadening the geographic reach, especially in Asia. Each company is developing new payloads, linkers, and antibody formats to decrease toxicity and enhance clinical efficacy. These are manifestations not only of innovation, but of intense competition that's driving global development and access.

Technology Platforms, Collaborations & Agreements

Technology platforms are the biggest differentiator in breast cancer ADCs. Companies are optimizing conjugation methods, linker chemistry, and payload delivery systems. For instance, bispecific ADCs (BsADCs), targeting two antigens at the same time, are being introduced as a next-generation answer for tumor heterogeneity. Part of the success of Enhertu lies in its high drug-to-antibody ratio and stable linker technology.

Collaborations are also driving expansion. Pfizer's acquisition of Seagen added propriety ADC platforms to its fold. Academic research institution-industry collaborations, like in the form of clinical trial partnerships,are speeding up candidate development. Licensing deals and local manufacturing support through CDMOs are also making access wider, particularly across emerging markets like India, China, and Latin America.

Report Indicating Future Direction Of Breast Cancer Antibody Drug Conjugates

This report predicts that breast cancer will continue to be the predominant indication for ADC innovation and commercialization. With additional candidates making their way into late-stage trials, and combination regimens demonstrating early efficacy, the future is directed toward more personalized and targeted therapy. Emerging innovations to watch are bispecific ADCs, increased biomarker testing, use in neoadjuvant/adjuvant treatment, and use in early-stage disease.

Regulatory momentum, investment capital, and scientific advancements are all coming together to pave the way for ADCs to be a cornerstone in the treatment of breast cancer. With an active pipeline, mounting international approvals, and growing indications, breast cancer ADCs can change the face of oncology care.

1. Introduction To Breast Cancer Antibody Drug Conjugates

2. Antibody Drug Conjugates As Breast Cancer Targeted Therapy

2.1 Mechanism Of Antibody Drug Conjugates
2.2 Applications & Advantages In Breast Cancer
2.3 Comparison With Traditional Therapies
2.4 Breast Cancer Antibody Drug Conjugates Combination Therapies

3. Generations Of Breast Cancer Antibody Drug Conjugates

3.1 Antibody Drug Conjugates - Evolution
3.2 Next Generation Antibody Drug Conjugates Prospects

4. Commercially Approved Breast Cancer Antibody Drug Conjugates By Brand Name, Company & Indication

5. Global Breast Cancer Antibody Drug Conjugates Market Outlook

5.1 Current Market Scenario
5.2 Global Breast Cancer Antibody Drug Conjugates Market Trends & Development
5.3 Future Growth Avenues

6. Global Cancer Antibody Drug Conjugates Research & Market Trends By Region

6.1 US
6.2 China
6.3 Europe
6.4 South Korea
6.5 Australia
6.6 Canada
6.7 Japan
6.8 UK
6.9 India
6.10 Latin America

7. Approved Breast Cancer Antibody Drug Conjugates - Patent, Dosage & Price Analysis

This Chapter Gives Insight On 7 Approved Breast Cancer Antibody Drug Conjugates

7.1 Kadcyla
- 7.1.1 Overview, Availability & Patent Insight
- 7.1.2 P ricing & Dosage Insight

7.7 Aidixi
- 7.7.1 Overview & Availability Insight

8. Approved Breast Cancer Antibody Drug Conjugates Sales Insights

8.1 Kadcyla
8.2 Enhertu
8.3 Trodelvy
8.4 Datroway

9. Global Cancer Antibody Drug Conjugates Clinical Trials Overview

9.1 By Phase
9.2 By Indication
9.3 By Company
9.4 By Country

10. Global Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

10.1 Research
10.2 Preclinical
10.3 Phase I
10.4 Phase I/II
10.5 Phase II
10.6 Phase II/III
10.7 Phase III
10.8 Preregistration
10.9 Registered

11. Marketed Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

12. Cancer Antibody Drug Conjugates Development Platforms By Company

13. Global Cancer Antibody Drug Conjugates Market Overview

13.1 Key Market Growth Drivers
13.2 Challenges For Market Growth

14. Competitive Landscape

14.1 ADC Therapeutics
14.2 AstraZeneca
14.3 Biocytogen
14.4 Biokin
14.5 Bristol Myers Squibb
14.6 Daiichi Sankyo
14.7 Duality Biologics
14.8 Eli Lilly
14.9 Gilead
14.10 Immunogen
14.11 Innovent Biologics
14.12 LigaChem Biosciences
14.13 Merck
14.14 Pfizer
14.15 Roche

简介目录图表

List of Figures

Figure 2-1: Antibody Drug Conjugates - General Working Mechanism
Figure 2-2: Advantages Of Antibody Drug Conjugates
Figure 2-3: Antibody Drug Conjugate Combinations In Studies
Figure 3-1: Cancer Antibody Drug Conjugates - Opportunities For Next Generation Development
Figure 5-1: Global - Breast Cancer Antibody Drug Conjugates Market (US$ Million), 2020-2025
Figure 5-2: Global - Breast Cancer Antibody Drug Conjugate Sales By Drugs (US$ Million), H1'2025
Figure 5-3: Global - Cancer Antibody Drug Conjugate Market Share By Drugs (%), H1'2025
Figure 5-4: Global - Breast Cancer Antibody Drug Conjugate Market (US$ Million), Q1 & Q2'2025
Figure 5-5: Global - Breast Cancer Antibody Drug Conjugate Sales By Drugs (US$ Million), 2024
Figure 5-6: Global - Breast Cancer Antibody Drug Conjugate Market Share By Drugs (%), 2024
Figure 5-7: Global - Breast Cancer Antibody Drug Conjugate Market (US$ Million), Q1 -Q4'2024
Figure 5-8: Global - Breast Cancer Antibody Drug Conjugate Market By Drugs (US$ Million), 2023
Figure 5-9: Global - Cancer Antibody Drug Conjugate Market Share By Drugs (%), 2023
Figure 5-10: D926QC00001 Phase 3 (NCT06112379) Study - Initiation & Completion Year
Figure 5-11: TQB2102-III-01 Phase 3 (NCT06561607) Study - Initiation & Completion Year
Figure 5-12: IZABRIGHT-Breast01 Phase 2/3 (NCT06926868) Study - Initiation & Completion Year
Figure 5-13: STARt-002 Phase 1/2 (NCT06827613) Study - Initiation & Completion Year
Figure 5-14: Global - Breast Cancer Antibody Drug Conjugate Market Forecast (US$ Billion), 2026 - 2030
Figure 6-1: India - Branded v/s Biosimilar Trastuzumab Emtansine Price by Supply (US$), September'2025
Figure 7-1: US - Kadcyla FDA Approval Year By Indication
Figure 7-2: Kadcyla - Approval Year By Region
Figure 7-3: US - Kadcyla FDA Approval & Patent Expiration Year
Figure 7-4: Kadcyla - Cost of Supply In US & Europe (US$), September'2025
Figure 7-5: Kadcyla - Recommended Dose after 1st & 2nd Dose Reduction (mg/kg)
Figure 7-6: Enhertu - Approval Year By Region
Figure 7-7: US - Polivy FDA Approval Year by Indication
Figure 7-8: Enhertu - FDA Orphan Drug Designation & Exclusivity Expiration Year
Figure 7-9: Enhertu - Cost of 100 mg Supply In US & Europe (US$), September'2025
Figure 7-10: US - Trodelvy FDA Approval by Indication
Figure 7-11: Trodelvy - Approval Year By Region
Figure 7-12: Trodelvy - Patent Expiration By Region
Figure 7-13: Trodelvy - Cost of Supply In US & Europe (US$), September'2025
Figure 7-14: Ujvira - Cost of 100 mg & 160 mg Supply in India (US$), September'2025
Figure 7-15: Datroway - Cost of 100 mg Supply In US & Europe (US$), September'2025
Figure 8-1: Kadcyla - Global Sales (US$ Million), 2020-2025
Figure 8-2: Kadcyla - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 8-3: Kadcyla - Global Sales By Region (%), H1'2025
Figure 8-4: Kadcyla - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 8-5: Kadcyla - Global Sales By Region (US$ Million), 2024
Figure 8-6: Kadcyla - Global Sales By Region (%), 2024
Figure 8-7: Kadcyla - US Annual Sales (US$ Million), 2020-2025
Figure 8-8: Kadcyla - US Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 8-9: Kadcyla - US Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 8-10: Kadcyla - Europe Annual Sales (US$ Million), 2020-2025
Figure 8-11: Kadcyla - Europe Quarterly Sales (US$ Million), Q1'2025
Figure 8-12: Kadcyla - Europe Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 8-13: Kadcyla - Japan Annual Sales (US$ Million), 2020-2025
Figure 8-14: Kadcyla - Japan Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 8-15: Kadcyla - Japan Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 8-16: Kadcyla - ROW Annual Sales (US$ Million), 2020-2025
Figure 8-17: Kadcyla - ROW Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 8-18: Kadcyla - ROW Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 8-19: Enhertu - Global Annual Sales (US$ Million), 2020-2025
Figure 8-20: Enhertu - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 8-21: Enhertu - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 8-22: Trodelvy - Global Annual Sales (US$ Million), 2020-2025
Figure 8-23: Trodelvy - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 8-24: Trodelvy - Annual Sales By Region (US$ Million), 2025
Figure 8-25: Trodelvy - Annual Sales By Region (%), 2025
Figure 8-26: Trodelvy - Global Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 8-27: Trodelvy - Annual Sales By Region (US$ Million), 2024
Figure 8-28: Trodelvy - Annual Sales By Region (%), 2024
Figure 8-29: Trodelvy - US Annual Sales (US$ Million), 2020-2025
Figure 8-30: Trodelvy - US Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 8-31: Trodelvy - US Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 8-32: Trodelvy - Europe Annual Sales (US$ Million), 2020-2025
Figure 8-33: Trodelvy - Europe Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 8-34: Trodelvy - Europe Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 8-35: Trodelvy - ROW Annual Sales (US$ Million), 2022-2025
Figure 8-36: Trodelvy - ROW Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 8-37: Trodelvy - ROW Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 8-38: Datroway - Global Annual Sales (US$ Million), 2025
Figure 8-39: Datroway - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 9-1: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Phase, 2025 Till 2030
Figure 9-2: Global- Cancer Antibody Drug Conjugate In Clinical Trials By Indication, 2025 Till 2030
Figure 9-3: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Company, 2025 Till 2030
Figure 9-4: Global - Cancer Antibody Drug Conjugate In Clinical Pipeline By Country, 2025 Till 2030
Figure 12-1: Proprietary ADC Technology - Seagen
Figure 12-2: ALE.P02 & ALE.P03 - Alentis Therapeutics
Figure 12-3: TRAAC - Tallac Therapeutics
Figure 12-4: ATAC - Heidelberg Pharma
Figure 12-5: Tub-tag(R) & P5 - Tubulis

List of Tables

Table 2-1: Comparison Between Antibody Drug Conjugates & Traditional Cancer Therapies
Table 2-2: Breast Cancer - Ongoing Antibody Drug Conjugate Combination Clinical Trials
Table 3-1: Breast Cancer - Approved Second Generation Antibody Drug Conjugates
Table 3-2: Breast Cancer - Approved Third Generation Antibody Drug Conjugates
Table 3-3: Fourth Generation Antibody Drug Conjugates - Examples
Table 4-1: Breast Cancer - Approved Antibody Drug Conjugates, September'2025
Table 5-1: Breast Cancer - Approved Antibody Drug Conjugates
Table 6-1: US - Approved Breast Cancer Antibody Drug Conjugates, September'2025
Table 6-2: China - Approved Antibody Drug Conjugates, September'2025
Table 6-3: EU - Approved Cancer Antibody Drug Conjugates, September'2025
Table 6-4: Australia - Approved Cancer Antibody Drug Conjugates, September'2025
Table 6-5: Canada - Approved Cancer Antibody Drug Conjugates, September'2025
Table 6-6: Japan - Approved Cancer Antibody Drug Conjugates, September'2025
Table 6-7: UK - Approved Antibody Drug Conjugates, September'2025
Table 7-1: Datroway - Premedication & Concomitant Medications
Table 7-2: Datroway - Recommended Dosage Reductions for Adverse Reactions

02-2729-4219

+886-2-2729-4219

License/价格

乳癌抗体药物复合体的全球市场:市场机会，专利，价格，认证核可药的销售额和临床试验趋势(2030年)

Global Breast Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030

目录

第1章乳癌抗体药物复合体的简介

第2章乳癌的标靶治疗的抗体药物复合体

第3章乳癌抗体药物复合体的世代

第4章市售已通过核准的乳癌抗体药物复合体(品牌名，公司，各适应症)

第5章全球乳癌抗体药物复合体市场展望

第6章全球癌症抗体药物复合体的调查与市场趋势(各地区)

第七章：已核准的乳癌抗体-药物偶联物－专利、剂量与价格分析

第八章：已核准乳癌抗体偶联药物的销售洞察

第9章全球癌症抗体药物复合体的临床试验概要

第10章全球的癌症抗体药物复合体的临床试验的洞察(企业，国家，适应症，各期)

第11章上市的癌症抗体药物复合体的临床试验:企业，国家，适应症，各期

第12章各企业癌症抗体药物复合体开发平台

第13章全球癌症抗体药物复合体市场概要

第14章竞争情形

Table of Contents